Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis

Journal of Infection

Volumn 67, Issue 5, 2013, Pages 424-432

  Pettit, April C ^a   Bethel, James ^b   Hirsch Moverman, Yael ^c   Colson, Paul W ^c   Sterling, Timothy R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WESTAT   (United States)

^c Mailman School of Public Health   (United States)

Author keywords

Adverse effects; Alcohol use; Female sex; Latent tuberculosis infection; Mycobacterium tuberculosis

Indexed keywords

ISONIAZID; RIFAMPICIN;

ADULT; ADVERSE DRUG REACTION; ALCOHOL CONSUMPTION; ARTICLE; CANADA; DARK URINE; DISEASE SEVERITY; DIZZINESS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EYE YELLOWING; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARESTHESIA; PROSPECTIVE STUDY; RASH; RISK FACTOR; SKIN DISCOLORATION; SKIN PRURITUS; SKIN YELLOWING; STOMACH UPSET; UNITED STATES; VOMITING; WEAKNESS;

ADVERSE EFFECTS; ALCOHOL USE; FEMALE SEX; LATENT TUBERCULOSIS INFECTION; MYCOBACTERIUM TUBERCULOSIS;

ADULT; ALCOHOL DRINKING; ANTITUBERCULAR AGENTS; CANADA; FEMALE; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SEX FACTORS; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 84884699680     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2013.07.015     Document Type: Article

References (31)

1. Bennett D.E., Courval J.M., Onorato I., Agerto T., Gibson J.D., Lambert L., et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. Am J Respir Crit Care Med 2008, 177(3):348-355.
2. Geng E., Kreiswirth B., Driver C., Li J., Burzynski J., DellaLatta P., et al. Changes in the transmission of tuberculosis in New York City from 1990 to 1999. N Engl J Med 2002, 346(19):1453-1458.
3. Small P.M., Hopewell P.C., Singh S.P., Paz A., Parsonnet J., Ruston D.C., et al. The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N Engl J Med 1994, 330(24):1703-1709.
4. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000, 49(RR-6):1-51.
5. Horsburgh C.R. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004, 350(20):2060-2067.
6. Jereb J., Etkind S.C., Joglar O.T., Moore M., Taylor Z. Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999. Int J Tuberc Lung Dis 2003, 7(12 Suppl. 3):S384-S390.
7. LoBue P.A., Moser K.S. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003, 168(4):443-447.
8. Horsburgh C.R., Goldberg S., Bethel J., Chen S., Colson P.W., Hirsch-moverman Y., et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2010, 137(2):401-409.
9. Hirsch-Moverman Y., Daftary A., Franks J., Colson P.W. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis 2008, 12(11):1235-1254.
10. Steele M.A., Burk R.F., DesPrez R.M. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991, 99(2):465-471.
11. Nolan C.M., Goldberg S.V., Buskin S.E. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. J Am Med Assoc 1999, 281(11):1014-1018.
12. Garibaldi R.A., Drusin R.E., Ferebee S.H., Gregg M.B. Isoniazid-associated hepatitis. Report of an outbreak. Am Rev Respir Dis 1972, 106(3):357-365.
13. Kopanoff D.E., Snider D.E., Caras G.J. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978, 117(6):991-1001.
14. Fernandez-Villar A., Sopena B., Vazquez R., Ulloa F., Fluiters E., Mosteiro M., et al. Isoniazid hepatotoxicity among drug users: the role of hepatitis C. Clin Infect Dis 2003, 36(3):293-298.
15. Patel P.A., Voigt M.D. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol 2002, 97(5):1198-1203.
16. Franks A.L., Binkin N.J., Snider D.E., Rokaw W.M., Becker S. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep 1989, 104(2):151-155.
17. Saukkonen J.J., Cohn D.L., Jasmer R.M., Schenker S., Jereb J.A., Nolan C.M., et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006, 174(8):935-952.
18. Snider D.E., Caras G.J. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992, 145(2 Pt 1):494-497.
19. Snider D.E. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980, 61(4):191-196.
20. Chin D.P., DeRiemer K., Small P.M., de Leon A.P., Steinhart R., Schecter G.F., et al. Differences in contributing factors to tuberculosis incidence in U.S.-born and foreign-born persons. Am J Respir Crit Care Med 1998, 158(6):1797-1803.
21. Schluger N.W., Huberman R., Wolinsky N., Dooley R., Rom W.N., Holzman R.S. Tuberculosis infection and disease among persons seeking social services in New York City. Int J Tuberc Lung Dis 1997, 1(1):31-37.
22. Selwyn P.A., Sckell B.M., Alcabes P., Friedland G.H., Klein R.S., Schoenbaum E.E. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. J Am Med Assoc 1992, 268(4):504-509.
23. Lobato M.N., Reves R.R., Jasmer R.M., Grabau J.C., Bock N.N., Shang N., et al. Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons. Chest 2005, 127(4):1296-1303.
24. Gilroy S.A., Rogers M.A., Blair D.C. Treatment of latent tuberculosis infection in patients aged > or=35 years. Clin Infect Dis 2000, 31(3):826-829.
25. Sterling T.R., Bethel J., Goldberg S., Weinfurter P., Yun L., Horsburgh C.R., et al. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med 2006, 173(8):927-931.
26. Colson P.W., Hirsch-Moverman Y., Bethel J., Vempaty P., Salcedo K., Wall K., et al. Acceptance of treatment for latent tuberculosis infection: prospective cohort study in the United States and Canada. Int J Tuberc Lung Dis 2013, 17(4):473-479.
27. Parkin D.P., Vandenplas S., Botha F.J., Vandenplas M.L., Seifart H.I., van Helden P.D., et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 1997, 155(5):1717-1722.
28. Huang Y.S., Chern H.D., Su W.J., Wu J.C., Lai S.L., Yang S.Y., et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002, 35(4):883-889.
29. Ohno M., Yamaguchi I., Yamamoto I., Fukuda T., Yokota S., Maekura R., et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 2000, 4(3):256-261.
30. Welfare M.R., Bassendine M.F., Daly A.K. The effect of NAT2 genotype and gender on the metabolism of caffeine in nonsmoking subjects. Br J Clin Pharmacol 2000, 49(3):240-243.
31. Welfare M.R., Cooper J., Bassendine M.F., Daly A.K. Relationship between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of England. Carcinogenesis 1997, 18(7):1351-1354.